Compugen Advances COM701 Trial in Ovarian Cancer Maintenance Therapy
Event summary
- Compugen presented a trial-in-progress poster on the MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress 2026.
- COM701, a potential first-in-class anti-PVRIG antibody, is being evaluated as a maintenance therapy in relapsed platinum-sensitive ovarian cancer.
- Initial data from the trial is expected by Q1 2027.
- The trial is led by Dr. Oladapo Yeku from Massachusetts General Hospital.
The big picture
Compugen's presentation at the ESMO Gynaecological Cancers Congress highlights the company's focus on leveraging AI/ML for drug discovery in the immuno-oncology space. The MAIA-ovarian trial represents a strategic shift towards maintenance therapy in relapsed platinum-sensitive ovarian cancer, an area with no established standard of care. The trial's adaptive platform design allows for flexible evaluation of COM701's potential, positioning Compugen to capitalize on the growing demand for targeted cancer therapies.
What we're watching
- Clinical Efficacy
- How the differentiated biology of the PVRIG pathway will translate into clinical efficacy in the MAIA-ovarian trial.
- Regulatory Pathway
- Whether the initial data from the trial will support further development and potential regulatory approval of COM701.
- Competitive Landscape
- The pace at which Compugen can differentiate COM701 in the crowded ovarian cancer treatment market.
Related topics